[
 {
  "event_date": "2026-07-18",
  "ticker": "BMY",
  "asset": "mezigdomide",
  "event_type": "READOUT",
  "event_window": "Jul 18, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05552976",
  "source_url": "https://clinicaltrials.gov/study/NCT05552976"
 },
 {
  "event_date": "2026-07-25",
  "ticker": "BMY",
  "asset": "deucravacitinib",
  "event_type": "READOUT",
  "event_window": "Jul 25, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT04036435",
  "source_url": "https://clinicaltrials.gov/study/NCT04036435"
 },
 {
  "event_date": "2026-07-27",
  "ticker": "REGN",
  "asset": "fianlimab",
  "event_type": "READOUT",
  "event_window": "Jul 27, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05608291",
  "source_url": "https://clinicaltrials.gov/study/NCT05608291"
 },
 {
  "event_date": "2026-07-31",
  "ticker": "HRMY",
  "asset": "pitolisant",
  "event_type": "READOUT",
  "event_window": "Jul 2026",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06366464",
  "source_url": "https://clinicaltrials.gov/study/NCT06366464"
 },
 {
  "event_date": "2026-07-31",
  "ticker": "LXRX",
  "asset": "sotagliflozin",
  "event_type": "READOUT",
  "event_window": "Jul 2026",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06481891",
  "source_url": "https://clinicaltrials.gov/study/NCT06481891"
 },
 {
  "event_date": "2026-07-31",
  "ticker": "JAZZ",
  "asset": "zanidatamab",
  "event_type": "READOUT",
  "event_window": "Jul 31, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05152147",
  "source_url": "https://clinicaltrials.gov/study/NCT05152147"
 },
 {
  "event_date": "2026-08-01",
  "ticker": "MRK",
  "asset": "tulisokibart",
  "event_type": "READOUT",
  "event_window": "Aug 1, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06052059",
  "source_url": "https://clinicaltrials.gov/study/NCT06052059"
 },
 {
  "event_date": "2026-08-24",
  "ticker": "AZN",
  "asset": "camizestrant",
  "event_type": "READOUT",
  "event_window": "Aug 24, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT04711252",
  "source_url": "https://clinicaltrials.gov/study/NCT04711252"
 },
 {
  "event_date": "2026-08-30",
  "ticker": "PFE",
  "asset": "elranatamab",
  "event_type": "READOUT",
  "event_window": "Aug 30, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06152575",
  "source_url": "https://clinicaltrials.gov/study/NCT06152575"
 },
 {
  "event_date": "2026-08-31",
  "ticker": "PHVS",
  "asset": "deucrictibant",
  "event_type": "READOUT",
  "event_window": "Aug 2026",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06669754",
  "source_url": "https://clinicaltrials.gov/study/NCT06669754"
 },
 {
  "event_date": "2026-08-31",
  "ticker": "SBFM",
  "asset": "lerotinib",
  "event_type": "READOUT",
  "event_window": "Aug 2026",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT04415853",
  "source_url": "https://clinicaltrials.gov/study/NCT04415853"
 },
 {
  "event_date": "2026-08-31",
  "ticker": "SLGL",
  "asset": "patidegib",
  "event_type": "READOUT",
  "event_window": "Aug 2026",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06050122",
  "source_url": "https://clinicaltrials.gov/study/NCT06050122"
 },
 {
  "event_date": "2026-08-31",
  "ticker": "LLY",
  "asset": "retatrutide",
  "event_type": "READOUT",
  "event_window": "Aug 2026",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06260722",
  "source_url": "https://clinicaltrials.gov/study/NCT06260722"
 },
 {
  "event_date": "2026-09-01",
  "ticker": "INCY",
  "asset": "tafasitamab",
  "event_type": "READOUT",
  "event_window": "Sep 1, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT04824092",
  "source_url": "https://clinicaltrials.gov/study/NCT04824092"
 },
 {
  "event_date": "2026-09-27",
  "ticker": "BIIB",
  "asset": "litifilimab",
  "event_type": "READOUT",
  "event_window": "Sep 27, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT04961567",
  "source_url": "https://clinicaltrials.gov/study/NCT04961567"
 },
 {
  "event_date": "2026-09-28",
  "ticker": "MLTX",
  "asset": "sonelokimab",
  "event_type": "READOUT",
  "event_window": "Sep 28, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06768671",
  "source_url": "https://clinicaltrials.gov/study/NCT06768671"
 },
 {
  "event_date": "2026-09-30",
  "ticker": "AZN",
  "asset": "datopotamab deruxtecan",
  "event_type": "READOUT",
  "event_window": "Sep 30, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06417814",
  "source_url": "https://clinicaltrials.gov/study/NCT06417814"
 },
 {
  "event_date": "2026-09-30",
  "ticker": "KURA",
  "asset": "daunorubicin",
  "event_type": "READOUT",
  "event_window": "Sep 30, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT03117751",
  "source_url": "https://clinicaltrials.gov/study/NCT03117751"
 },
 {
  "event_date": "2026-09-30",
  "ticker": "DAN",
  "asset": "erwinia asparaginase",
  "event_type": "READOUT",
  "event_window": "Sep 30, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT03117751",
  "source_url": "https://clinicaltrials.gov/study/NCT03117751"
 },
 {
  "event_date": "2026-09-30",
  "ticker": "BIIB",
  "asset": "litifilimab",
  "event_type": "READOUT",
  "event_window": "Sep 30, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT04895241",
  "source_url": "https://clinicaltrials.gov/study/NCT04895241"
 },
 {
  "event_date": "2026-09-30",
  "ticker": "DAN",
  "asset": "mercaptopurine",
  "event_type": "READOUT",
  "event_window": "Sep 30, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT03117751",
  "source_url": "https://clinicaltrials.gov/study/NCT03117751"
 },
 {
  "event_date": "2026-09-30",
  "ticker": "AZN",
  "asset": "monalizumab",
  "event_type": "READOUT",
  "event_window": "Sep 30, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05221840",
  "source_url": "https://clinicaltrials.gov/study/NCT05221840"
 },
 {
  "event_date": "2026-09-30",
  "ticker": "DAN",
  "asset": "nelarabine",
  "event_type": "READOUT",
  "event_window": "Sep 30, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT03117751",
  "source_url": "https://clinicaltrials.gov/study/NCT03117751"
 },
 {
  "event_date": "2026-09-30",
  "ticker": "AZN",
  "asset": "oleclumab",
  "event_type": "READOUT",
  "event_window": "Sep 30, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05221840",
  "source_url": "https://clinicaltrials.gov/study/NCT05221840"
 },
 {
  "event_date": "2026-09-30",
  "ticker": "DAN",
  "asset": "pegaspargase",
  "event_type": "READOUT",
  "event_window": "Sep 30, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT03117751",
  "source_url": "https://clinicaltrials.gov/study/NCT03117751"
 },
 {
  "event_date": "2026-10-19",
  "ticker": "BMY",
  "asset": "deucravacitinib",
  "event_type": "READOUT",
  "event_window": "Oct 19, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05617677",
  "source_url": "https://clinicaltrials.gov/study/NCT05617677"
 },
 {
  "event_date": "2026-10-20",
  "ticker": "BIIB",
  "asset": "litifilimab",
  "event_type": "READOUT",
  "event_window": "Oct 20, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05531565",
  "source_url": "https://clinicaltrials.gov/study/NCT05531565"
 },
 {
  "event_date": "2026-10-26",
  "ticker": "NVS",
  "asset": "inclisiran",
  "event_type": "READOUT",
  "event_window": "Oct 26, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05360446",
  "source_url": "https://clinicaltrials.gov/study/NCT05360446"
 },
 {
  "event_date": "2026-10-28",
  "ticker": "MRK",
  "asset": "belzutifan",
  "event_type": "READOUT",
  "event_window": "Oct 28, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05239728",
  "source_url": "https://clinicaltrials.gov/study/NCT05239728"
 },
 {
  "event_date": "2026-10-29",
  "ticker": "MRK",
  "asset": "belzutifan",
  "event_type": "READOUT",
  "event_window": "Oct 29, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT04736706",
  "source_url": "https://clinicaltrials.gov/study/NCT04736706"
 },
 {
  "event_date": "2026-10-31",
  "ticker": "NUVL",
  "asset": "alectinib",
  "event_type": "READOUT",
  "event_window": "Oct 31, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT03178552",
  "source_url": "https://clinicaltrials.gov/study/NCT03178552"
 },
 {
  "event_date": "2026-10-31",
  "ticker": "VTRS",
  "asset": "cenerimod",
  "event_type": "READOUT",
  "event_window": "Oct 31, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05648500",
  "source_url": "https://clinicaltrials.gov/study/NCT05648500"
 },
 {
  "event_date": "2026-10-31",
  "ticker": "IMMP",
  "asset": "eftilagimod alpha",
  "event_type": "READOUT",
  "event_window": "Oct 31, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05747794",
  "source_url": "https://clinicaltrials.gov/study/NCT05747794"
 },
 {
  "event_date": "2026-10-31",
  "ticker": "NVS",
  "asset": "inclisiran",
  "event_type": "READOUT",
  "event_window": "Oct 2026",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT03705234",
  "source_url": "https://clinicaltrials.gov/study/NCT03705234"
 },
 {
  "event_date": "2026-10-31",
  "ticker": "SBFM",
  "asset": "minoxidil",
  "event_type": "READOUT",
  "event_window": "Oct 2026",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05888922",
  "source_url": "https://clinicaltrials.gov/study/NCT05888922"
 },
 {
  "event_date": "2026-10-31",
  "ticker": "LLY",
  "asset": "retatrutide",
  "event_type": "READOUT",
  "event_window": "Oct 2026",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06297603",
  "source_url": "https://clinicaltrials.gov/study/NCT06297603"
 },
 {
  "event_date": "2026-10-31",
  "ticker": "OGN",
  "asset": "tapinarof",
  "event_type": "READOUT",
  "event_window": "Oct 2026",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05172726",
  "source_url": "https://clinicaltrials.gov/study/NCT05172726"
 },
 {
  "event_date": "2026-11-13",
  "ticker": "COGT",
  "asset": "midazolam",
  "event_type": "READOUT",
  "event_window": "Nov 13, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05646862",
  "source_url": "https://clinicaltrials.gov/study/NCT05646862"
 },
 {
  "event_date": "2026-11-30",
  "ticker": "CGON",
  "asset": "cretostimogene grenadenorepvec",
  "event_type": "READOUT",
  "event_window": "Nov 2026",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06111235",
  "source_url": "https://clinicaltrials.gov/study/NCT06111235"
 },
 {
  "event_date": "2026-11-30",
  "ticker": "DAN",
  "asset": "erwinia asparaginase",
  "event_type": "READOUT",
  "event_window": "Nov 30, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT03020030",
  "source_url": "https://clinicaltrials.gov/study/NCT03020030"
 },
 {
  "event_date": "2026-11-30",
  "ticker": "NAMS",
  "asset": "obicetrapib",
  "event_type": "READOUT",
  "event_window": "Nov 2026",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05202509",
  "source_url": "https://clinicaltrials.gov/study/NCT05202509"
 },
 {
  "event_date": "2026-11-30",
  "ticker": "LLY",
  "asset": "orforglipron",
  "event_type": "READOUT",
  "event_window": "Nov 2026",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06649045",
  "source_url": "https://clinicaltrials.gov/study/NCT06649045"
 },
 {
  "event_date": "2026-11-30",
  "ticker": "DAN",
  "asset": "pegaspargase",
  "event_type": "READOUT",
  "event_window": "Nov 30, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT03020030",
  "source_url": "https://clinicaltrials.gov/study/NCT03020030"
 },
 {
  "event_date": "2026-11-30",
  "ticker": "LLY",
  "asset": "tirzepatide",
  "event_type": "READOUT",
  "event_window": "Nov 2026",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06914895",
  "source_url": "https://clinicaltrials.gov/study/NCT06914895"
 },
 {
  "event_date": "2026-12-01",
  "ticker": "VNDA",
  "asset": "tradipitant",
  "event_type": "READOUT",
  "event_window": "Dec 1, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT07446439",
  "source_url": "https://clinicaltrials.gov/study/NCT07446439"
 },
 {
  "event_date": "2026-12-02",
  "ticker": "MRK",
  "asset": "enlicitide decanoate",
  "event_type": "READOUT",
  "event_window": "Dec 2, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT07216482",
  "source_url": "https://clinicaltrials.gov/study/NCT07216482"
 },
 {
  "event_date": "2026-12-02",
  "ticker": "PFE",
  "asset": "mevrometostat",
  "event_type": "READOUT",
  "event_window": "Dec 2, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06629779",
  "source_url": "https://clinicaltrials.gov/study/NCT06629779"
 },
 {
  "event_date": "2026-12-02",
  "ticker": "PFE",
  "asset": "ritlecitinib higher",
  "event_type": "READOUT",
  "event_window": "Dec 2, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT07029711",
  "source_url": "https://clinicaltrials.gov/study/NCT07029711"
 },
 {
  "event_date": "2026-12-02",
  "ticker": "PFE",
  "asset": "ritlecitinib lower",
  "event_type": "READOUT",
  "event_window": "Dec 2, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT07029711",
  "source_url": "https://clinicaltrials.gov/study/NCT07029711"
 },
 {
  "event_date": "2026-12-02",
  "ticker": "MRK",
  "asset": "rosuvastatin calcium",
  "event_type": "READOUT",
  "event_window": "Dec 2, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT07216482",
  "source_url": "https://clinicaltrials.gov/study/NCT07216482"
 },
 {
  "event_date": "2026-12-21",
  "ticker": "PFE",
  "asset": "ritlecitinib",
  "event_type": "READOUT",
  "event_window": "Dec 21, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06873945",
  "source_url": "https://clinicaltrials.gov/study/NCT06873945"
 },
 {
  "event_date": "2026-12-26",
  "ticker": "INCY",
  "asset": "povorcitinib",
  "event_type": "READOUT",
  "event_window": "Dec 26, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06212999",
  "source_url": "https://clinicaltrials.gov/study/NCT06212999"
 },
 {
  "event_date": "2026-12-30",
  "ticker": "INTS",
  "asset": "pazopanib",
  "event_type": "READOUT",
  "event_window": "Dec 30, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT03592472",
  "source_url": "https://clinicaltrials.gov/study/NCT03592472"
 },
 {
  "event_date": "2026-12-30",
  "ticker": "PFE",
  "asset": "vepdegestrant",
  "event_type": "READOUT",
  "event_window": "Dec 30, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05909397",
  "source_url": "https://clinicaltrials.gov/study/NCT05909397"
 },
 {
  "event_date": "2026-12-31",
  "ticker": "PFE",
  "asset": "axitinib",
  "event_type": "READOUT",
  "event_window": "Dec 31, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05059522",
  "source_url": "https://clinicaltrials.gov/study/NCT05059522"
 },
 {
  "event_date": "2026-12-31",
  "ticker": "AZN",
  "asset": "darolutamide",
  "event_type": "READOUT",
  "event_window": "Dec 2026",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT03903835",
  "source_url": "https://clinicaltrials.gov/study/NCT03903835"
 },
 {
  "event_date": "2026-12-31",
  "ticker": "PFE",
  "asset": "disitamab vedotin",
  "event_type": "READOUT",
  "event_window": "Dec 31, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05302284",
  "source_url": "https://clinicaltrials.gov/study/NCT05302284"
 },
 {
  "event_date": "2026-12-31",
  "ticker": "IONS",
  "asset": "donidalorsen",
  "event_type": "READOUT",
  "event_window": "Dec 2026",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05392114",
  "source_url": "https://clinicaltrials.gov/study/NCT05392114"
 },
 {
  "event_date": "2026-12-31",
  "ticker": "MRK",
  "asset": "ibrutinib",
  "event_type": "READOUT",
  "event_window": "Dec 31, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT01804686",
  "source_url": "https://clinicaltrials.gov/study/NCT01804686"
 },
 {
  "event_date": "2026-12-31",
  "ticker": "SMMT",
  "asset": "ivonescimab",
  "event_type": "READOUT",
  "event_window": "Dec 2026",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06767527",
  "source_url": "https://clinicaltrials.gov/study/NCT06767527"
 },
 {
  "event_date": "2026-12-31",
  "ticker": "PFE",
  "asset": "lorlatanib",
  "event_type": "READOUT",
  "event_window": "Dec 31, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05059522",
  "source_url": "https://clinicaltrials.gov/study/NCT05059522"
 },
 {
  "event_date": "2026-12-31",
  "ticker": "ABBV",
  "asset": "lutikizumab",
  "event_type": "READOUT",
  "event_window": "Dec 2026",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06468228",
  "source_url": "https://clinicaltrials.gov/study/NCT06468228"
 },
 {
  "event_date": "2026-12-31",
  "ticker": "SNY",
  "asset": "migalastat",
  "event_type": "READOUT",
  "event_window": "Dec 31, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT04020055",
  "source_url": "https://clinicaltrials.gov/study/NCT04020055"
 },
 {
  "event_date": "2026-12-31",
  "ticker": "GNLX",
  "asset": "olvimulogene nanivacirepvec",
  "event_type": "READOUT",
  "event_window": "Dec 2026",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05281471",
  "source_url": "https://clinicaltrials.gov/study/NCT05281471"
 },
 {
  "event_date": "2026-12-31",
  "ticker": "UTHR",
  "asset": "ralinepag",
  "event_type": "READOUT",
  "event_window": "Dec 2026",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT03683186",
  "source_url": "https://clinicaltrials.gov/study/NCT03683186"
 },
 {
  "event_date": "2026-12-31",
  "ticker": "DMAC",
  "asset": "recombinant human tissue kallikrein",
  "event_type": "READOUT",
  "event_window": "Dec 2026",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05065216",
  "source_url": "https://clinicaltrials.gov/study/NCT05065216"
 },
 {
  "event_date": "2026-12-31",
  "ticker": "LLY",
  "asset": "retatrutide",
  "event_type": "READOUT",
  "event_window": "Dec 2026",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06662383",
  "source_url": "https://clinicaltrials.gov/study/NCT06662383"
 },
 {
  "event_date": "2026-12-31",
  "ticker": "GILD",
  "asset": "sacituzumab govitecan hziy",
  "event_type": "READOUT",
  "event_window": "Dec 2026",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT04639986",
  "source_url": "https://clinicaltrials.gov/study/NCT04639986"
 },
 {
  "event_date": "2026-12-31",
  "ticker": "PFE",
  "asset": "talazoparib",
  "event_type": "READOUT",
  "event_window": "Dec 31, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05059522",
  "source_url": "https://clinicaltrials.gov/study/NCT05059522"
 },
 {
  "event_date": "2026-12-31",
  "ticker": "VOR",
  "asset": "telitacicept",
  "event_type": "READOUT",
  "event_window": "Dec 31, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT07249632",
  "source_url": "https://clinicaltrials.gov/study/NCT07249632"
 },
 {
  "event_date": "2026-12-31",
  "ticker": "PFE",
  "asset": "utomilumab",
  "event_type": "READOUT",
  "event_window": "Dec 31, 2026",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05059522",
  "source_url": "https://clinicaltrials.gov/study/NCT05059522"
 },
 {
  "event_date": "2027-01-04",
  "ticker": "AZN",
  "asset": "laroprovstat",
  "event_type": "READOUT",
  "event_window": "Jan 4, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT07000136",
  "source_url": "https://clinicaltrials.gov/study/NCT07000136"
 },
 {
  "event_date": "2027-01-04",
  "ticker": "MRK",
  "asset": "rescue medications",
  "event_type": "READOUT",
  "event_window": "Jan 4, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06356311",
  "source_url": "https://clinicaltrials.gov/study/NCT06356311"
 },
 {
  "event_date": "2027-01-04",
  "ticker": "MRK",
  "asset": "supportive care measures",
  "event_type": "READOUT",
  "event_window": "Jan 4, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06356311",
  "source_url": "https://clinicaltrials.gov/study/NCT06356311"
 },
 {
  "event_date": "2027-01-10",
  "ticker": "BMY",
  "asset": "mezigdomide",
  "event_type": "READOUT",
  "event_window": "Jan 10, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05519085",
  "source_url": "https://clinicaltrials.gov/study/NCT05519085"
 },
 {
  "event_date": "2027-01-11",
  "ticker": "AZN",
  "asset": "laroprovstat",
  "event_type": "READOUT",
  "event_window": "Jan 11, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT07000123",
  "source_url": "https://clinicaltrials.gov/study/NCT07000123"
 },
 {
  "event_date": "2027-01-13",
  "ticker": "SMMT",
  "asset": "ivonescimab",
  "event_type": "READOUT",
  "event_window": "Jan 13, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06951503",
  "source_url": "https://clinicaltrials.gov/study/NCT06951503"
 },
 {
  "event_date": "2027-01-15",
  "ticker": "IDYA",
  "asset": "darovasertib",
  "event_type": "READOUT",
  "event_window": "Jan 15, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05987332",
  "source_url": "https://clinicaltrials.gov/study/NCT05987332"
 },
 {
  "event_date": "2027-01-15",
  "ticker": "MLTX",
  "asset": "sonelokimab",
  "event_type": "READOUT",
  "event_window": "Jan 15, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06641089",
  "source_url": "https://clinicaltrials.gov/study/NCT06641089"
 },
 {
  "event_date": "2027-01-21",
  "ticker": "AMGN",
  "asset": "maridebart cafraglutide",
  "event_type": "READOUT",
  "event_window": "Jan 21, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06858839",
  "source_url": "https://clinicaltrials.gov/study/NCT06858839"
 },
 {
  "event_date": "2027-01-29",
  "ticker": "PFE",
  "asset": "disitamab vedotin",
  "event_type": "READOUT",
  "event_window": "Jan 29, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05911295",
  "source_url": "https://clinicaltrials.gov/study/NCT05911295"
 },
 {
  "event_date": "2027-02-04",
  "ticker": "MLTX",
  "asset": "sonelokimab",
  "event_type": "READOUT",
  "event_window": "Feb 4, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06641076",
  "source_url": "https://clinicaltrials.gov/study/NCT06641076"
 },
 {
  "event_date": "2027-02-11",
  "ticker": "NVS",
  "asset": "inclisiran",
  "event_type": "READOUT",
  "event_window": "Feb 11, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT07102628",
  "source_url": "https://clinicaltrials.gov/study/NCT07102628"
 },
 {
  "event_date": "2027-02-14",
  "ticker": "LLY",
  "asset": "tirzepatide",
  "event_type": "READOUT",
  "event_window": "Feb 14, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT07481747",
  "source_url": "https://clinicaltrials.gov/study/NCT07481747"
 },
 {
  "event_date": "2027-02-22",
  "ticker": "AZN",
  "asset": "laroprovstat",
  "event_type": "READOUT",
  "event_window": "Feb 22, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06834932",
  "source_url": "https://clinicaltrials.gov/study/NCT06834932"
 },
 {
  "event_date": "2027-02-26",
  "ticker": "AZN",
  "asset": "anifrolumab",
  "event_type": "READOUT",
  "event_window": "Feb 26, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05138133",
  "source_url": "https://clinicaltrials.gov/study/NCT05138133"
 },
 {
  "event_date": "2027-02-28",
  "ticker": "LLY",
  "asset": "orforglipron",
  "event_type": "READOUT",
  "event_window": "Feb 2027",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06672549",
  "source_url": "https://clinicaltrials.gov/study/NCT06672549"
 },
 {
  "event_date": "2027-02-28",
  "ticker": "GMAB",
  "asset": "rina",
  "event_type": "READOUT",
  "event_window": "Feb 2027",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06619236",
  "source_url": "https://clinicaltrials.gov/study/NCT06619236"
 },
 {
  "event_date": "2027-02-28",
  "ticker": "GILD",
  "asset": "sacituzumab govitecan hziy",
  "event_type": "READOUT",
  "event_window": "Feb 2027",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05382286",
  "source_url": "https://clinicaltrials.gov/study/NCT05382286"
 },
 {
  "event_date": "2027-03-01",
  "ticker": "NVO",
  "asset": "cagrilintide",
  "event_type": "READOUT",
  "event_window": "Mar 1, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT07011667",
  "source_url": "https://clinicaltrials.gov/study/NCT07011667"
 },
 {
  "event_date": "2027-03-13",
  "ticker": "RYTM",
  "asset": "setmelanotide",
  "event_type": "READOUT",
  "event_window": "Mar 13, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06760546",
  "source_url": "https://clinicaltrials.gov/study/NCT06760546"
 },
 {
  "event_date": "2027-03-18",
  "ticker": "MRK",
  "asset": "ibrutinib",
  "event_type": "READOUT",
  "event_window": "Mar 18, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT04212013",
  "source_url": "https://clinicaltrials.gov/study/NCT04212013"
 },
 {
  "event_date": "2027-03-22",
  "ticker": "REGN",
  "asset": "fianlimab",
  "event_type": "READOUT",
  "event_window": "Mar 22, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06246916",
  "source_url": "https://clinicaltrials.gov/study/NCT06246916"
 },
 {
  "event_date": "2027-03-24",
  "ticker": "NVS",
  "asset": "ianalumab",
  "event_type": "READOUT",
  "event_window": "Mar 24, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05639114",
  "source_url": "https://clinicaltrials.gov/study/NCT05639114"
 },
 {
  "event_date": "2027-03-31",
  "ticker": "ARGX",
  "asset": "efgartigimod",
  "event_type": "READOUT",
  "event_window": "Mar 2027",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT04833894",
  "source_url": "https://clinicaltrials.gov/study/NCT04833894"
 },
 {
  "event_date": "2027-03-31",
  "ticker": "IONS",
  "asset": "olezarsen",
  "event_type": "READOUT",
  "event_window": "Mar 2027",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05681351",
  "source_url": "https://clinicaltrials.gov/study/NCT05681351"
 },
 {
  "event_date": "2027-03-31",
  "ticker": "AAPG",
  "asset": "olverembatinib",
  "event_type": "READOUT",
  "event_window": "Mar 31, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06640361",
  "source_url": "https://clinicaltrials.gov/study/NCT06640361"
 },
 {
  "event_date": "2027-03-31",
  "ticker": "MDGL",
  "asset": "resmetirom",
  "event_type": "READOUT",
  "event_window": "Mar 2027",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT04951219",
  "source_url": "https://clinicaltrials.gov/study/NCT04951219"
 },
 {
  "event_date": "2027-03-31",
  "ticker": "AZN",
  "asset": "rezvilutamide",
  "event_type": "READOUT",
  "event_window": "Mar 2027",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT07241416",
  "source_url": "https://clinicaltrials.gov/study/NCT07241416"
 },
 {
  "event_date": "2027-03-31",
  "ticker": "PFE",
  "asset": "ritlecitinib",
  "event_type": "READOUT",
  "event_window": "Mar 31, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06163326",
  "source_url": "https://clinicaltrials.gov/study/NCT06163326"
 },
 {
  "event_date": "2027-03-31",
  "ticker": "NVS",
  "asset": "tisagenlecleucel",
  "event_type": "READOUT",
  "event_window": "Mar 31, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT04094311",
  "source_url": "https://clinicaltrials.gov/study/NCT04094311"
 },
 {
  "event_date": "2027-03-31",
  "ticker": "ONC",
  "asset": "zanubrutinib",
  "event_type": "READOUT",
  "event_window": "Mar 2027",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT04002297",
  "source_url": "https://clinicaltrials.gov/study/NCT04002297"
 },
 {
  "event_date": "2027-04-12",
  "ticker": "NVS",
  "asset": "ianalumab",
  "event_type": "READOUT",
  "event_window": "Apr 12, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05624749",
  "source_url": "https://clinicaltrials.gov/study/NCT05624749"
 },
 {
  "event_date": "2027-04-14",
  "ticker": "PFE",
  "asset": "tofacitinib",
  "event_type": "READOUT",
  "event_window": "Apr 14, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT04624230",
  "source_url": "https://clinicaltrials.gov/study/NCT04624230"
 },
 {
  "event_date": "2027-04-20",
  "ticker": "AZN",
  "asset": "camizestrant",
  "event_type": "READOUT",
  "event_window": "Apr 20, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05774951",
  "source_url": "https://clinicaltrials.gov/study/NCT05774951"
 },
 {
  "event_date": "2027-04-25",
  "ticker": "LLY",
  "asset": "lebrikizumab",
  "event_type": "READOUT",
  "event_window": "Apr 25, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06526182",
  "source_url": "https://clinicaltrials.gov/study/NCT06526182"
 },
 {
  "event_date": "2027-04-27",
  "ticker": "AMGN",
  "asset": "maridebart cafraglutide",
  "event_type": "READOUT",
  "event_window": "Apr 27, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06987695",
  "source_url": "https://clinicaltrials.gov/study/NCT06987695"
 },
 {
  "event_date": "2027-04-30",
  "ticker": "MRK",
  "asset": "ifinatamab deruxtecan",
  "event_type": "READOUT",
  "event_window": "Apr 30, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06203210",
  "source_url": "https://clinicaltrials.gov/study/NCT06203210"
 },
 {
  "event_date": "2027-04-30",
  "ticker": "NVS",
  "asset": "iptacopan",
  "event_type": "READOUT",
  "event_window": "Apr 30, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06517758",
  "source_url": "https://clinicaltrials.gov/study/NCT06517758"
 },
 {
  "event_date": "2027-05-02",
  "ticker": "PFE",
  "asset": "abrocitinib",
  "event_type": "READOUT",
  "event_window": "May 2, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06807268",
  "source_url": "https://clinicaltrials.gov/study/NCT06807268"
 },
 {
  "event_date": "2027-05-11",
  "ticker": "NVO",
  "asset": "cagrilintide",
  "event_type": "READOUT",
  "event_window": "May 11, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT07220642",
  "source_url": "https://clinicaltrials.gov/study/NCT07220642"
 },
 {
  "event_date": "2027-05-12",
  "ticker": "NVO",
  "asset": "cagrilintide",
  "event_type": "READOUT",
  "event_window": "May 12, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT07220759",
  "source_url": "https://clinicaltrials.gov/study/NCT07220759"
 },
 {
  "event_date": "2027-05-18",
  "ticker": "TAK",
  "asset": "zasocitinib",
  "event_type": "READOUT",
  "event_window": "May 18, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06671483",
  "source_url": "https://clinicaltrials.gov/study/NCT06671483"
 },
 {
  "event_date": "2027-05-19",
  "ticker": "MRK",
  "asset": "nemtabrutinib",
  "event_type": "READOUT",
  "event_window": "May 19, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05624554",
  "source_url": "https://clinicaltrials.gov/study/NCT05624554"
 },
 {
  "event_date": "2027-05-31",
  "ticker": "TEVA",
  "asset": "deuruxolitinib",
  "event_type": "READOUT",
  "event_window": "May 2027",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT03898479",
  "source_url": "https://clinicaltrials.gov/study/NCT03898479"
 },
 {
  "event_date": "2027-05-31",
  "ticker": "LLY",
  "asset": "orforglipron",
  "event_type": "READOUT",
  "event_window": "May 2027",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT07613307",
  "source_url": "https://clinicaltrials.gov/study/NCT07613307"
 },
 {
  "event_date": "2027-05-31",
  "ticker": "VOR",
  "asset": "telitacicept",
  "event_type": "READOUT",
  "event_window": "May 2027",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06456580",
  "source_url": "https://clinicaltrials.gov/study/NCT06456580"
 },
 {
  "event_date": "2027-06-02",
  "ticker": "NVS",
  "asset": "pelabresib",
  "event_type": "READOUT",
  "event_window": "Jun 2, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06401356",
  "source_url": "https://clinicaltrials.gov/study/NCT06401356"
 },
 {
  "event_date": "2027-06-07",
  "ticker": "MRK",
  "asset": "belzutifan",
  "event_type": "READOUT",
  "event_window": "Jun 7, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05899049",
  "source_url": "https://clinicaltrials.gov/study/NCT05899049"
 },
 {
  "event_date": "2027-06-18",
  "ticker": "REGN",
  "asset": "mibavademab",
  "event_type": "READOUT",
  "event_window": "Jun 18, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT07220772",
  "source_url": "https://clinicaltrials.gov/study/NCT07220772"
 },
 {
  "event_date": "2027-06-30",
  "ticker": "PFE",
  "asset": "binimetinib",
  "event_type": "READOUT",
  "event_window": "Jun 2027",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05615818",
  "source_url": "https://clinicaltrials.gov/study/NCT05615818"
 },
 {
  "event_date": "2027-06-30",
  "ticker": "AZN",
  "asset": "datopotamab deruxtecan",
  "event_type": "READOUT",
  "event_window": "Jun 30, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06564844",
  "source_url": "https://clinicaltrials.gov/study/NCT06564844"
 },
 {
  "event_date": "2027-06-30",
  "ticker": "PHVS",
  "asset": "deucrictibant",
  "event_type": "READOUT",
  "event_window": "Jun 2027",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05396105",
  "source_url": "https://clinicaltrials.gov/study/NCT05396105"
 },
 {
  "event_date": "2027-06-30",
  "ticker": "IMMP",
  "asset": "eftilagimod alfa",
  "event_type": "READOUT",
  "event_window": "Jun 2027",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06726265",
  "source_url": "https://clinicaltrials.gov/study/NCT06726265"
 },
 {
  "event_date": "2027-06-30",
  "ticker": "PFE",
  "asset": "encorafenib",
  "event_type": "READOUT",
  "event_window": "Jun 2027",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05615818",
  "source_url": "https://clinicaltrials.gov/study/NCT05615818"
 },
 {
  "event_date": "2027-06-30",
  "ticker": "GMAB",
  "asset": "epcoritamab",
  "event_type": "READOUT",
  "event_window": "Jun 2027",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05578976",
  "source_url": "https://clinicaltrials.gov/study/NCT05578976"
 },
 {
  "event_date": "2027-06-30",
  "ticker": "IMNN",
  "asset": "niraparib",
  "event_type": "READOUT",
  "event_window": "Jun 2027",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT03651206",
  "source_url": "https://clinicaltrials.gov/study/NCT03651206"
 },
 {
  "event_date": "2027-06-30",
  "ticker": "AZN",
  "asset": "rilvegostomig",
  "event_type": "READOUT",
  "event_window": "Jun 30, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06564844",
  "source_url": "https://clinicaltrials.gov/study/NCT06564844"
 },
 {
  "event_date": "2027-06-30",
  "ticker": "GILD",
  "asset": "sacituzumab govitecan hziy",
  "event_type": "READOUT",
  "event_window": "Jun 2027",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05633654",
  "source_url": "https://clinicaltrials.gov/study/NCT05633654"
 },
 {
  "event_date": "2027-06-30",
  "ticker": "AMGN",
  "asset": "sotorasib",
  "event_type": "READOUT",
  "event_window": "Jun 30, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05920356",
  "source_url": "https://clinicaltrials.gov/study/NCT05920356"
 },
 {
  "event_date": "2027-06-30",
  "ticker": "JAZZ",
  "asset": "zanidatamab",
  "event_type": "READOUT",
  "event_window": "Jun 2027",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05615818",
  "source_url": "https://clinicaltrials.gov/study/NCT05615818"
 },
 {
  "event_date": "2027-07-02",
  "ticker": "NVO",
  "asset": "ziltivekimab",
  "event_type": "READOUT",
  "event_window": "Jul 2, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05636176",
  "source_url": "https://clinicaltrials.gov/study/NCT05636176"
 },
 {
  "event_date": "2027-07-05",
  "ticker": "AMGN",
  "asset": "tarlatamab",
  "event_type": "READOUT",
  "event_window": "Jul 5, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06211036",
  "source_url": "https://clinicaltrials.gov/study/NCT06211036"
 },
 {
  "event_date": "2027-07-28",
  "ticker": "AZN",
  "asset": "datopotamab deruxtecan",
  "event_type": "READOUT",
  "event_window": "Jul 28, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06103864",
  "source_url": "https://clinicaltrials.gov/study/NCT06103864"
 },
 {
  "event_date": "2027-07-30",
  "ticker": "GMAB",
  "asset": "acasunlimab",
  "event_type": "READOUT",
  "event_window": "Jul 30, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06635824",
  "source_url": "https://clinicaltrials.gov/study/NCT06635824"
 },
 {
  "event_date": "2027-07-30",
  "ticker": "AZN",
  "asset": "darolutamide",
  "event_type": "READOUT",
  "event_window": "Jul 30, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05794906",
  "source_url": "https://clinicaltrials.gov/study/NCT05794906"
 },
 {
  "event_date": "2027-07-30",
  "ticker": "PFE",
  "asset": "ritlecitinib",
  "event_type": "READOUT",
  "event_window": "Jul 30, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06072183",
  "source_url": "https://clinicaltrials.gov/study/NCT06072183"
 },
 {
  "event_date": "2027-07-31",
  "ticker": "AZN",
  "asset": "dapagliflozin",
  "event_type": "READOUT",
  "event_window": "Jul 2027",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05374291",
  "source_url": "https://clinicaltrials.gov/study/NCT05374291"
 },
 {
  "event_date": "2027-07-31",
  "ticker": "LLY",
  "asset": "retatrutide",
  "event_type": "READOUT",
  "event_window": "Jul 2027",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT07232719",
  "source_url": "https://clinicaltrials.gov/study/NCT07232719"
 },
 {
  "event_date": "2027-08-04",
  "ticker": "PFE",
  "asset": "elranatamab",
  "event_type": "READOUT",
  "event_window": "Aug 4, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05317416",
  "source_url": "https://clinicaltrials.gov/study/NCT05317416"
 },
 {
  "event_date": "2027-08-07",
  "ticker": "AZN",
  "asset": "tezepelumab",
  "event_type": "READOUT",
  "event_window": "Aug 7, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT07363642",
  "source_url": "https://clinicaltrials.gov/study/NCT07363642"
 },
 {
  "event_date": "2027-08-09",
  "ticker": "BMY",
  "asset": "golcadomide",
  "event_type": "READOUT",
  "event_window": "Aug 9, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06356129",
  "source_url": "https://clinicaltrials.gov/study/NCT06356129"
 },
 {
  "event_date": "2027-08-20",
  "ticker": "ARWR",
  "asset": "zodasiran",
  "event_type": "READOUT",
  "event_window": "Aug 20, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT07037771",
  "source_url": "https://clinicaltrials.gov/study/NCT07037771"
 },
 {
  "event_date": "2027-08-27",
  "ticker": "AZN",
  "asset": "ravulizumab",
  "event_type": "READOUT",
  "event_window": "Aug 27, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT07596784",
  "source_url": "https://clinicaltrials.gov/study/NCT07596784"
 },
 {
  "event_date": "2027-08-31",
  "ticker": "AAPG",
  "asset": "lisaftoclax",
  "event_type": "READOUT",
  "event_window": "Aug 2027",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06319456",
  "source_url": "https://clinicaltrials.gov/study/NCT06319456"
 },
 {
  "event_date": "2027-08-31",
  "ticker": "LLY",
  "asset": "orforglipron",
  "event_type": "READOUT",
  "event_window": "Aug 2027",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06972459",
  "source_url": "https://clinicaltrials.gov/study/NCT06972459"
 },
 {
  "event_date": "2027-08-31",
  "ticker": "CRNX",
  "asset": "paltusotine",
  "event_type": "READOUT",
  "event_window": "Aug 2027",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT07087054",
  "source_url": "https://clinicaltrials.gov/study/NCT07087054"
 },
 {
  "event_date": "2027-08-31",
  "ticker": "ABBV",
  "asset": "telisotuzumab adizutecan",
  "event_type": "READOUT",
  "event_window": "Aug 2027",
  "date_precision": "month",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06614192",
  "source_url": "https://clinicaltrials.gov/study/NCT06614192"
 },
 {
  "event_date": "2027-08-31",
  "ticker": "MRK",
  "asset": "tocilizumab",
  "event_type": "READOUT",
  "event_window": "Aug 31, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT06084936",
  "source_url": "https://clinicaltrials.gov/study/NCT06084936"
 },
 {
  "event_date": "2027-09-01",
  "ticker": "NVO",
  "asset": "cagrilintide",
  "event_type": "READOUT",
  "event_window": "Sep 1, 2027",
  "date_precision": "day",
  "confidence": "medium",
  "source": "clinicaltrials",
  "nct_id": "NCT05669755",
  "source_url": "https://clinicaltrials.gov/study/NCT05669755"
 }
]